Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/27175Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Manos, Kate | - |
| dc.contributor.author | Grigg, Andrew P | - |
| dc.date | 2021-08-04 | - |
| dc.date.accessioned | 2021-08-09T05:49:18Z | - |
| dc.date.available | 2021-08-09T05:49:18Z | - |
| dc.date.issued | 2021-08-04 | - |
| dc.identifier.citation | Leukemia & Lymphoma 2021; 62(14): 3552-3554 | en |
| dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/27175 | - |
| dc.language.iso | eng | - |
| dc.title | Safe administration of obinutuzumab to rituximab-intolerant patients. | en |
| dc.type | Journal Article | en |
| dc.identifier.journaltitle | Leukemia & Lymphoma | en |
| dc.identifier.affiliation | Clinical Haematology | en |
| dc.identifier.doi | 10.1080/10428194.2021.1961232 | en |
| dc.type.content | Text | en |
| dc.identifier.pubmedid | 34348074 | - |
| local.name.researcher | Grigg, Andrew P | |
| item.fulltext | No Fulltext | - |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| item.cerifentitytype | Publications | - |
| item.openairetype | Journal Article | - |
| item.grantfulltext | none | - |
| item.languageiso639-1 | en | - |
| crisitem.author.dept | Clinical Haematology | - |
| crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
| crisitem.author.dept | Clinical Haematology | - |
| Appears in Collections: | Journal articles | |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.